Abstract
Objective: PartoSure is a bedside test for the prediction of time-to-spontaneous preterm delivery by the detection of placental alpha microglobulin-1 (PAMG-1). The objectives of this study were to further determine the test’s efficacy in predicting delivery within 7 or 14 days from testing, and to compare it with fetal fibronectin (fFN) and cervical length (CL) measurement by transvaginal ultrasound.
Study design: The study population consisted of 203 consecutively recruited women with singleton pregnancies between 200/7 and 366/7 weeks of gestation with symptoms of preterm labor, clinically intact membranes, and cervical dilatation of ≤3 cm. PartoSure and CL were performed on all patients and the test-to-spontaneous-delivery interval was calculated. In a sub-segment of patients, the QuikCheck fFN test was used.
Results: The sensitivities for PartoSure (n=203), fFN (n=66), and CL (n=203) for predicting imminent spontaneous preterm delivery within 7 days were 80%, 50%, and 57%, respectively. The specificities were 95%, 72%, and 73% for PartoSure, fFN and CL, respectively. The NPVs were 96%, 87%, and 89% for PartoSure, fFN and CL, respectively. The PPVs were 76%, 29%, and 30% for PartoSure, fFN and CL, respectively.
Conclusion: PAMG-1 detection by PartoSure is the single best predictor of imminent spontaneous delivery within 7 days compared to fFN and CL. In settings where CL is used as an initial screen, PartoSure has the greatest clinical utility in patients with CL between 15 and 35 mm. In situations where CL is not an initial screen, PartoSure is the most accurate test compared to fFN and CL.
Sources of financial support:
NeitherAmniSure® International LLC (a QIAGEN® Company) nor Hologic® Inc. provided funding for the trial. PartoSure and QuikCheck fFN test kits were obtained free of charge. The investigators do not have any financial relationship with either company.
References
[1] ACOG Practice Bulletin. Assessment of risk factors for preterm birth. Clinical management guidelines for obstetrician-gynecologists. Number 31, October 2001. (Replaces Technical Bulletin number 206, June 1995; Committee Opinion number 172, May 1996; Committee Opinion number 187, September 1997; Committee Opinion number 198, February 1998; and Committee Opinion number 251, January 2001). Obstet Gynecol. 2001;98:709−16.Search in Google Scholar
[2] ACOG Practice Bulletin. Management of preterm labor. Number 43, May 2003. Int J Gynaecol Obstet. 2003;82:127−35.10.1016/S0020-7292(03)00247-9Search in Google Scholar
[3] Institute of Medicine. Preterm birth: causes, consequences, and prevention. Washington, DC: National Academies Press; 2007.Search in Google Scholar
[4] Lucovnik M, Chambliss LR, Garfield RE. Costs of unnecessary admissions and treatments for “threatened preterm labor”. Am J Obstet Gynecol. 2013;209:217.e1−3.10.1016/j.ajog.2013.06.046Search in Google Scholar PubMed
[5] Di Renzo GC, CaberoRoura L, Facchinetti F, the EAPM-Study Group on “Preterm Birth”. Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Matern Fetal Neonatal Med. 2011;24:659−67.10.3109/14767058.2011.553694Search in Google Scholar PubMed PubMed Central
[6] Duff, P. Preterm Premature Rupture of Membranes. In: UpToDate, Basow DS (Ed), UpToDate, Waltham, MA, 2012.Search in Google Scholar
[7] Güngördük K, Asicioglu O, Besimoglu B, Güngördük OC, Yildirm G, Ark C, et al. Labor induction in term premature rupture of membranes: comparison between oxytocin and dinoprostone followed 6 hours later by oxytocin. Am J Obstet Gynecol. 2012;206:60.e1–8.10.1016/j.ajog.2011.07.035Search in Google Scholar PubMed
[8] Lee SE, Park JS, Norwitz ER, Kim KW, Park HS, Jun JK. Measurement of placental a-microglobulin-1 in cervicovaginal discharge to diagnose rupture of membranes. Obstet Gynecol. 2007;109:634–40.10.1097/01.AOG.0000252706.46734.0aSearch in Google Scholar PubMed
[9] Lee SM, Lee J, Seong HS, Lee SE, Park JS, Romero R, et al. The clinical significance of a positive Amnisure test TM in women with term labor with intact membranes. J Matern Fetal Neonatal Med. 2009;22:305–10.10.1080/14767050902801694Search in Google Scholar PubMed PubMed Central
[10] Lee MS, Romero R, Park JW, Kim SM, Park CW, Korzeniewski S, et al. The clinical significance of a positive Amnisuretest(™) in women with preterm labor. J Matern Fetal Neonatal Med. 2012;25:1690−8.10.3109/14767058.2012.657279Search in Google Scholar PubMed PubMed Central
[11] Sukchaya K, Phupong V. A comparative study of positive rate of placental alpha-microglobulin-1 test in pre-term pregnant women with and without uterine contraction. J Obstet Gynaecol. 2013;33:566−8.10.3109/01443615.2013.807786Search in Google Scholar PubMed
[12] Ehsanipoor RM, Swank M, Jwa SC, Wing DA, Tarabulsi G, Blakemore K. Placental alpha-microglobulin-1 in vaginal secretions as a predictor of preterm birth in women with evidence of preterm labor. Society of Gynecological Investigation. T-079. Mar 27 2014.Search in Google Scholar
[13] Lee SM, Yoon BH, Park CW, Kim SM, Park JW. Intra-amniotic inflammation in patients with a positive Amnisure test in preterm labor and intact membranes. Am J Obstet Gynecol. 2011;204:S209.10.1016/j.ajog.2010.10.543Search in Google Scholar
[14] Nikolova T, Bayev O, Nikolova N, Di Renzo GC. Evaluation of a novel placental alpha microglobulin-1 (PAMG-1) test to predict spontaneous preterm delivery. J Perinat Med. 2013;13:1−5.10.1515/jpm-2013-0234Search in Google Scholar PubMed
[15] Plaut MM, Smith W, Kennedy K. Fetal fibronectin: the impact of a rapid test on the treatment of women with preterm labor symptoms. Am J Obstet Gynecol. 2003;188:1588−93; discussion 1593−5.10.1067/mob.2003.390Search in Google Scholar PubMed
[16] Grobman WA, Welshman EE, Calhoun EA. Does fetal fibronectin use in the diagnosis of preterm labor affect physician behavior and health care costs? A randomized trial. Am J Obstet Gynecol. 2004;191:235−40.10.1016/j.ajog.2003.11.034Search in Google Scholar PubMed
[17] Ness A, Visintine J, Ricci E, Berghella V. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. Am J Obstet Gynecol. 2007;197:426.e1−7.10.1016/j.ajog.2007.07.017Search in Google Scholar PubMed
[18] ACOG Practice Bulletin. Management of preterm labor. Obstet Gynecol. 2012;119:1308–17.10.1097/AOG.0b013e31825af2f0Search in Google Scholar PubMed
[19] Boots AB, Sanchez-Ramos L, Bowers DM, Kaunitz AM, Zamora J, Schlattmann P. The short-term prediction of preterm birth: a systematic review and diagnostic metaanalysis. Am J Obstet Gynecol. 2014;210:54.e1−10.10.1016/j.ajog.2013.09.004Search in Google Scholar PubMed
[20] DeFranco EA, Lewis DF, Odibo AO. Improving the screening accuracy for preterm labor: is the combination of fetal fibronectin and cervical length in symptomatic patients a useful predictor of preterm birth? A systematic review. Am J Obstet Gynecol. 2013;208:233.e1−6.10.1016/j.ajog.2012.12.015Search in Google Scholar PubMed
The authors stated that there are no conflicts of interest regarding the publication of this article.
Paper Presentation Information:
Preliminary findings of this investigation were presented at the World Congress of Perinatal Medicine in Moscow, Russia in June 2013 by Professor Oleg Bayev, MD.
©2015 by De Gruyter
